DZD 1516
Alternative Names: DZD-1516Latest Information Update: 12 Mar 2026
At a glance
- Originator Dizal Pharmaceutical
- Class Antineoplastics
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 positive breast cancer
Most Recent Events
- 12 Mar 2026 DZD 1516 is still in phase I trials for HER2-positive-breast-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, Combination therapy) in USA, China (PO)
- 11 Dec 2023 Phase I development is ongoing in USA and China (Dizal Pharmaceutical pipeline, December 2023)
- 05 Sep 2022 Efficacy, Adverse events and Pharmacokinetics data from a phase I trial in Breast cancer presented at the European Society for Medical Oncology Annual Meeting (ESMO-2022)